论文部分内容阅读
本文介绍一种快速测定尿中6—羟甲蝶吟的方法,并就其临床意义和实用价值进行了探讨。资料表明:26例健康人、4例癌症患者、11例未经化疗的各类白血病患者尿中排泄的6—羟甲蝶呤水平分别为0.815±0.131μg/ml.1.233±0.215μg/ml、1.693±0.406μg/ml,后两者均显著高于健康人对照组(P<0.001)。而4例非癌性疾病患者的尿蝶呤含量与健康人的数值接近,恶性肿瘤术后及白血病化疗后尿蝶呤明显降低。结果提示:这一简单、有效、无创伤性的测定方法可作为临床癌症诊断及疗效评估的一种手段。
This article describes a rapid determination of urinary 6-hydroxymetyrin method, and its clinical significance and practical value were discussed. The data showed that the levels of urinary excretion of 6-methotrexate in 26 healthy people, 4 cancer patients and 11 non-chemotherapy leukemia patients were 0.815 ± 0.131μg / ml and 1.233 ± 0.215μg / ml respectively, 1.693 ± 0.406μg / ml, both of which were significantly higher than those of healthy control group (P <0.001). However, the urinary excretion of 4 non-cancerous patients was similar to that of healthy people. The urinary excretion of patients with malignant tumor and leukemia after chemotherapy was significantly lower. The results suggest that this simple, effective and noninvasive method can be used as a tool to evaluate clinical diagnosis and treatment of cancer.